Gilenya® (fingolimod): New contraindication in pregnant women and in women of childbearing potential who are not using effective contraception

User Rating: 4 / 5

Star ActiveStar ActiveStar ActiveStar ActiveStar Inactive
 

 

Description

In Malaysia, fingolimod is indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adult patients and in paediatric patients of 10 years old and above to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.

Based on European post-marketing surveillance of congenital anomalies, fingolimod has been associated with a two-fold increased risk of major congenital malformations when used during pregnancy as compared to the rate observed in the general population (2-3%).1 The most commonly reported major malformations are congenital heart diseases, renal and musculoskeletal abnormalities.

Due to this risk, fingolimod is now contraindicated in pregnant women and in women of childbearing potential who are not using effective contraception.

The prescribing information of Gilenya® will be updated to reflect this new contraindication. On 18th August 2020, NPRA has approved a Direct Healthcare Professional Communication (DHPC) letter issued by Novartis (Malaysia) Sdn. Bhd. to highlight this safety issue. For further information, please contact your local sales person for a copy of the DHPC.

 

Reference(s):

  1. European Commission. European network of population-based registries for the epidemiological surveillance of congenital anomalies (EUROCAT). Available from: http://www.eurocat-network.eu

 

DISCLAIMER

This publication is aimed at health professionals. The information is meant to provide updates on medication safety issues, and not as a substitute for clinical judgement. While reasonable care has been taken to verify the accuracy of the information at the time of publication, the NPRA shall not be held liable for any loss whatsoever arising from the use of or reliance on this publication.

 

 

 

 

 

National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia.
  • Email: npra@npra.gov.my
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Site Last Modified

  • Last Modified: Friday 23 October 2020, 13:24:57.
© Copyright 2019 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA

Main Menu English

Choose Your Language